RE: 🔥🔥🔥🔥 breaking news 🚀🚀21 Jan 2025 00:58
The Nutt FDA Validation baby.
Exciting times
Prof. David Nutt, Chief Research Officer of Awakn, added, "The FDA's recognition of our development strategy, and their willingness to support progression to Phase 2b, further validates the potential of AWKN-002 as a therapeutic for AUD. We look forward to continuing our work to bring this promising treatment to patients in need."